Navigation Links
Third Wave strikes deal with Kaiser Permanente on cystic fibrosis reagents

MADISON - Third Wave Technologies has announced the launch of its Invader cystic fibrosis genotyping analyte-specific reagents. In conjunction with Invaders premiere, the company announced a new partnership with Kaiser Permanente, the largest non-profit health plan in the United States, ......

Full article >>> markets molecular diagnostics for a variety of DNA and RNA analysis applications.......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 03/31/04


Related biology technology :

1. Third Wave files countersuit vs. Digene in patent case
2. Third Wave reports net loss of $18.9M for 2006
3. Stratagene to pay Third Wave $10.75M in patent case
4. Third Wave responds to Digene patent lawsuit
5. Third Wave seeks approval of Cystic Fibrosis test
6. Third Wave Technologies to raise $14.9M through private debt
7. Third Wave reports $5.2M third quarter loss
8. Third Wave reports another loss, stronger sales
9. Napier joins board of Third Wave Technologies
10. Third Waves revenues rebound
11. Third Wave reports clinical growth, continued loss
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):